Therigy, LLC is committed to rapidly getting the latest treatment information into the hands of providers for HCV and other disease states.
Therigy, LLC announced recently it has updated its propriety specialty therapy management application, TherigySTM, to include clinical information critical to patient care based on the recent FDA approval of Viekira Pak on December 19, 2014.
“We monitor the drug pipeline and have invested heavily in the clinical staff required to rapidly update our product upon the FDA’s approval of new specialty therapies,” said Russel Allinson, RPh, MS, Therigy’s CEO and Chief Clinical Officer. “The team works hard to ensure our customers are getting the most up-to-date, robust, and accurate clinical content for the management of patients on specialty drug therapies.” Allinson added, “we accomplished the same with Gilead’s Harvoni when it was released on October 10th (2014) by getting the new clinical content into the hands of our customers by October 13th. Ultimately, we know timely product updates help our customers better serve their patients, resulting in improved patient outcomes.”
Therigy said its customers can expect to find complete and detailed information regarding Viekira Pak, along with the associated medical history, warnings and precautions, contraindications, medication and administration guide, side effects, teaching points, and resources.
“This recent release is part of a series of updates we’ve provided to our customers over the past several months as new developments have emerged in the treatment of HCV,” said Lily Duong, PharmD, Therigy’s Vice President of Clinical Programs. “Here at Therigy, we are committed to doing everything we can to get this type of valuable information in the hands of our customers as quickly as possible.”
In addition to the HCV disease state, TherigySTM provides detailed therapy management programs for the following therapeutic categories:
- Autoimmune Diseases
- Growth Hormone Deficiency
- Multiple Sclerosis
- Oral Oncology, Hematology
- Respiratory Syncytial Virus (RSV)
TherigySTM is the industry’s leading application for pharmacies to deliver specialty therapy management for improved patient outcomes. The HIPAA-compliant, software-as-a-service application integrates with dispensing systems and delivers pre-configured disease and therapy-specific clinical content for pharmacies to manage, track, and report customized data to payors and manufacturers.
About Therigy, LLC
Therigy is the trusted source for specialty solutions. We create leading web and mobile applications, provide consulting services, and deliver business intelligence for the specialty pharmaceutical market. Clients leverage Therigy’s in-depth knowledge, extensive experience, and advanced products to achieve clinical and economic success by aligning strategy, technology, and people.